Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
20.38
0.00 (0.00%)
Nov 28, 2025, 4:00 PM EST - Market closed
Nanobiotix Revenue
Nanobiotix had revenue of 26.64M EUR in the half year ending June 30, 2025, with 708.93% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M.
Revenue (ttm)
10.16M EUR
Revenue Growth
-75.93%
P/S Ratio
82.21
Revenue / Employee
94,065 EUR
Employees
108
Market Cap
980.86M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
| Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NBTX News
- 4 days ago - Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook - GlobeNewsWire
- 4 days ago - Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue - The Motley Fool
- 15 days ago - NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations - GlobeNewsWire
- 25 days ago - NANOBIOTIX to Participate in Investor Conferences the Week of November 10th - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 2 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewsWire